In the case of anti-PD-1 pretreatment, responsive melanoma exhibited elevated levels of CD8+ T-cell infiltration and expression of PD-L1 on tumor cells or immune cells; thus, these particular signatures might act as a potential biomarker for treatment responsiveness [170,171,172]. This evidence concerns the gene CD8A and neoplasm.